Skip to content
  • Technology
    • NULISA Platform
    • Attobody Platform
  • Products and Services
    • ARGO System
    • NULISA Multiplex Assays
    • NULISA Single-plex Assays
    • NULISA Custom Assays
    • Technology Access Program
  • Resources
    • Events & Webinars
    • Publications & Posters
    • White Papers
    • Alamar Blog
  • Company
    • About
    • News
    • Careers
  • Contact
Menu
  • Technology
    • NULISA Platform
    • Attobody Platform
  • Products and Services
    • ARGO System
    • NULISA Multiplex Assays
    • NULISA Single-plex Assays
    • NULISA Custom Assays
    • Technology Access Program
  • Resources
    • Events & Webinars
    • Publications & Posters
    • White Papers
    • Alamar Blog
  • Company
    • About
    • News
    • Careers
  • Contact
Search
Close this search box.

Attovia Therapeutics Launches with $60 Million Series A Financing to Unlock Potential of Novel Biparatopic Nanobody Platform

Company Formed by Alamar Biosciences and Frazier Life Sciences Attobody™ Platform Generates Small Format Binders for Hard-to-drug Targets FREMONT and MENLO PARK– June 20, 2023 – Alamar Biosciences, a company […]

Alamar Biosciences Unveils Novel Proteomics Platform with Best-in-Class Sensitivity and High Multiplexing Capability

Alamar Biosciences Unveils Novel Proteomics Platform with Best-in-Class Sensitivity and High Multiplexing Capability Multiplex analysis of 204 serum proteins with attomolar sensitivity and 10 logs dynamic range enables accurate measurement […]

Mologic and Alamar Biosciences collaborate to develop a next generation COVID-19 antigen test

• Mologic leverages Alamar’s ultra-high affinity antibodies for SARS-CoV-2 diagnostics • Partnership will facilitate rapid responses to future pandemics Bedfordshire, UK and Fremont, CA, US – 4 May 2022 – […]

SciNeuro Pharmaceuticals and Alamar Biosciences Collaborate to Discover Novel Therapeutic Antibodies for CNS Diseases

Fremont, CA and Rockville, MD – 15 February 2022 – Alamar Biosciences (Alamar), a platform company focused on transforming the field of proteomics to enable the early detection of cancer […]

Alamar Biosciences partners with Abcam to drive understanding of the human proteome

Alamar selects Abcam as a key provider of antibody content for its proprietary NULISA technology platform Fremont, CA, US and Cambridge, UK – 04 January 2022 – Alamar Biosciences (Alamar), […]

Alamar Biosciences Completes $80M Series B Fundraising to Bring Unprecedented Performance to the Proteomics Market

Fremont, CA, September 8, 2021 (PR NEWSWIRE) — Alamar Biosciences, Inc., a precision proteomics company that brings both ultra-high sensitivity and massively parallel scale to proteomic analysis, announced today that […]

Links

  • About
  • Technology
  • News
  • Careers

Contact

Alamar Biosciences, Inc.
47071 Bayside Pkwy
Fremont, CA 94538
1 (510) 626-9888
Fax: (510) 605-5062

Contact us
Linkedin Facebook Twitter

©2023 Alamar Biosciences, Inc. All rights reserved. | Legal | Privacy Policy

A Biotech Web Design Agency

  • Technology
    • NULISA Platform
    • Attobody Platform
  • Products and Services
    • ARGO System
    • NULISA Multiplex Assays
    • NULISA Single-plex Assays
    • NULISA Custom Assays
    • Technology Access Program
  • Resources
    • Events & Webinars
    • Publications & Posters
    • White Papers
    • Alamar Blog
  • Company
    • About
    • News
    • Careers
  • Contact
  • Technology
    • NULISA Platform
    • Attobody Platform
  • Products and Services
    • ARGO System
    • NULISA Multiplex Assays
    • NULISA Single-plex Assays
    • NULISA Custom Assays
    • Technology Access Program
  • Resources
    • Events & Webinars
    • Publications & Posters
    • White Papers
    • Alamar Blog
  • Company
    • About
    • News
    • Careers
  • Contact